Posted by Michael Wonder on 13 Jun 2024
Baricitinib for the treatment of patients with juvenile idiopathic arthritis
13 June 2024 - NICE is unable to make a recommendation on the use in the NHS of baricitinib (Olumiant) for the treatment of patients 2 years and older with juvenile idiopathic arthritis because Eli Lilly did not provide an evidence submission.
NICE will review this decision if Eli LIlly decides to make a submission.
